Autoimmune Haemolytic Anaemias Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Autoimmune Haemolytic Anaemias. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Autoimmune Haemolytic Anaemias receives a directional strategic score of 58/100. The synthesis combines unmet need (70/100), competitive intensity (96/100, where a higher value means more competition) and market attractiveness (83/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.

The reproducible entity is Patsnap disease ID 068f9838b3cc44c0b85968479230fa7b with MeSH identifier D000744. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Autoimmune Haemolytic Anaemias, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980–2016 Increasing Incidence and Prevalence of AcquiredHemolytic Anemias in Denmark, 1980–2016

1. Bottiger LE, Westerholm B. Acquired haemolytic anaemia. I. Incidence and aetiology. Acta Med Scand. 1973;193(3):223–226. doi:10.1111/j.0954-6820.1973.tb10567.x 2. Klein NP, Ray P, Carpenter D, et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010;28(4):1062–1068. doi:10.1016/j.vaccine.2009.10.115 3. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29(1):1–9. doi:10.1016/j.jaut.2007.05.002 4. Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–466. 5. Hill A, Platts PJ, Smith A, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108(11):985. doi:10.1182/blood.V108. 11.985.985 6. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4–5):143–150. doi:10.1016/j.blre.2010.06.004 7. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–125. doi:10.1016/S1568-9972(03) 00006-5 8. Dacie SJ. The immune haemolytic anaemias: a century of exciting progress in understanding. Br J Haematol. 2001;114(4):770–785. doi:10.1046/j.1365-2141.2001.02945.x 9. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258–271. doi:10.1002/ajh.10062 10. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in th

Review the underlying epidemiology source

Epidemiology signal 2: Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023

Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023 RESEARCH ARTICLE Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023 Sylvie Bozzi1, Siddhi Umarje2, Kalyani Hawaldar 2, Jennifer Tyma2, Brad Ward2, Jill Schinkel3, Barnabie Agatep3, Zulkarnain Pulungan 3, Natalia Petruski-Ivleva 2* 1 Sanofi, Gentilly, France, 2 Sanofi, Cambridge, Massachusetts, United States of America, 3 Inovalon, Bowie, Maryland, United States of America * natalia.petruski-ivleva@sanofi.com Abstract Background and aims Autoimmune hemolytic anemia (AIHA) and cold agglutinin disease (CAD) are debili­ tating conditions characterized by chronic hemolysis and severe anemia. The existing epidemiological estimates in the United States (US) remain limited because of the rarity of AIHA and CAD. This retrospective study aims to update the epidemiology of AIHA and CAD in the US from 2016 to 2023 by separately analyzing administra­ tive claims data from Optum’s de-identified Clinformatics® Data Mart (Optum CDM), Inovalon’s Medical Outcomes Research for Effectiveness and Economics (MORE2) Registry, and Medicare Fee for Service (FFS). OPEN ACCESS Citation: Bozzi S, Umarje S, Hawaldar K, Tyma J, Ward B, Schinkel J, et al. (2025) Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023. PLoS One 20(6): e0323843. https://doi-org.libproxy1.nus.edu.sg/10.1371/ journal.pone.0323843 Methods Editor: Omid Beiki, Karolinska Institutet, SWEDE

Review the underlying epidemiology source

Epidemiology signal 3: Epidemiology of Autoimmune Liver Disease

1. Kim BH, Kim YJ, Jeong SH, et al. Clinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study. J Gastroenterol Hepatol 2013;28: 128-134. 2. Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population- based prevalence, incidence, and disease burden of auto- immune hepatitis in South Korea. PLoS One 2017;12:e01823 91. 3. Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol 2019;34:1676-1684. 4. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nation- wide registry-based cohort study. J Hepatol 2014;60:612-617. 5. Danielsson Borssén Å, Marschall HU, Bergquist A, et al. Epidemiology and causes of death in a Swedish cohort of patients with auto- immune hepatitis. Scand J Gastroenterol 2017;52:1022-1028. 6. Lamba M, Ngu JH, Stedman CAM. Trends in incidence of auto- immune liver diseases and increasing incidence of autoimmune hepatitis. Clin Gastroenterol Hepatol 2021;19:573-579.e1. 7. Grønbaek L, Otete H, Ban L, et al. Incidence, prevalence and mor- tality of autoimmune hepatitis in England 1997-2015. A pop- ulation-based cohort study. Liver Int 2020;40:1634-1644. 8. Yoshizawa K, Joshita S, Matsumoto A, et al. Incidence and preva- lence of autoimmune hepatitis in the Ueda area, Japan. Hepatol Res 2016;46:878-883. 9. Tunio NA, Mansoor E, Sheriff MZ, Cooper GS, Sclair SN, Cohen SM. Epidemiology of autoimmune

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Autoimmune Haemolytic Anaemias, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Autoimmune Haemolytic Anaemias strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: IL-1β

Potent pro-inflammatory cytokine (PubMed:10653850, PubMed:12794819, PubMed:28331908, PubMed:3920526). Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and collagen production (PubMed:3920526). Promotes Th17 differentiation of T-cells. Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Plays a role in angiogenesis by inducing VEGF production synergistically with TNF and IL6 (PubMed:12794819). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33377178, PubMed:33883744). Acts as a sensor of S.pyogenes infection in skin: cleaved and activated by pyogenes SpeB protease, leading to an inflammatory response that prevents bacterial growth during invasive skin infection (PubMed:28331908).

The mechanism anchor for this landscape is IL1B. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 334 registered studies overall. Recent sampled records include:

• NCT07748533 — HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.; status Recruiting; phase Phase 1; sponsor Juventas Cell Therapy Ltd.; enrollment 9.
• JPRN-jRCT1050260137 — Cross-sectional Survey on Symptoms and Impact on Daily Life in Patients with Cold Agglutinin Disease (Cross-sectional Survey in Patients with Cold Agglutinin Disease); status 募集中; phase Not Applicable; sponsor not stated; enrollment 40.
• NCT07743242 — Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome; status Recruiting; phase Not Applicable; sponsor New valley university; enrollment 230.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Autoimmune Haemolytic Anaemias. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

The search identified 1 recent directly matched transaction records. Representative results:

• Recordati announces agreement to acquire the global rights to Enjaymo®, strengthening its rare diseases franchise (2024-10-04). Review rights, stage, territory, contingent milestones and disclosed economics before using it as a comparable.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Autoimmune Haemolytic Anaemias, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that IL1B is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Autoimmune Haemolytic Anaemias merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if IL1B modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Autoimmune Haemolytic Anaemias is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.